Science & Technology

Channels: Science & Technology | Financial Markets | Artificial Intelligence | Blockchain


Update on Base Editing Technology License

[2020.01.14, Tue 08:03] Option to exclusively license a novel Base Editing technology from Rutgers, The State University of New Jersey, for use in therapeutic, diagnostic and service applications. In January 2019, Horizon and Rutgers signed an Option Agreement and a Research Agreement, which granted Horizon an option to obtain an exclusive license to Rutgers' proprietary Base Editing technology for therapeutic, diagnostic and service applications. Horizon has now exercised its option and Rutgers has granted it an exclusive license to Rutgers' proprietary Base Editing technology. Base Editing is a novel technology that enables scientists to make edits to base pairs in DNA by recruiting specific Base Editing enzymes. "Exercising our option for this technology is potentially transformative for Horizon. Base Editing has the potential to revolutionise the treatment of genetic diseases. Over the past year, we completed a detailed evaluation phase of Rutgers' technology and are excited to now have an exclusive license for use in therapeutic, diagnostic and service applications."There is significant latent demand for access to Base Editing and we already have significant interest from potential partners interested in early access to this cutting-edge technology. Base Editing is a novel technology platform for engineering DNA or genes in cells, which allows scientists to make specific edits to base pairs in DNA or RNA by using an enzyme to change a single base of DNA into another. Compared with currently available gene editing methodologies such as CRISPR/Cas9, which creates "Cuts" in the gene that can lead to adverse or negative effects, this new technology allows for more accurate gene editing while reducing unintended genomic changes.
Read on FE Trustnet >   Google the news >>

<< Back


(c) 2019 Geo Glance